Otsuka Pakistan Limited has announced a major restructuring of its pharmaceutical manufacturing operations, including the closure of one production line and the proposed sale of selected pharmaceutical product rights, as the company reported a 14.6 per cent increase in net profit to Rs137.62 million for the quarter ended September 30, 2026.
According to financial results and material information disclosures submitted to the Pakistan Stock Exchange (PSX) on Wednesday, the pharmaceutical manufacturer recorded quarterly revenue of Rs1.147 billion, compared with Rs1.076 billion during the corresponding period last year, reflecting year-on-year growth of approximately 6.6 per cent.
The company’s Board of Directors, which met on October 28, approved the reorganisation of manufacturing facilities at its Hub Industrial Trading Estate plant in Lasbela, Balochistan, alongside the quarterly financial statements.
The restructuring involves transferring nine pharmaceutical products from Production Line-II to Production Line-I from January 1, 2027, while the machinery installed on the discontinued production line, carrying a value of approximately Rs81 million, is expected to remain idle.
The company has also announced plans to transfer and sell certain pharmaceutical product registrations, authorisations, technical information and associated inventory, subject to regulatory approvals and due diligence.
Quarterly Profit Climbs To Rs137.62 Million
Otsuka Pakistan reported net profit of Rs137.617 million for the July–September 2026 quarter, compared with Rs120.078 million in the corresponding quarter of 2025.
The increase represents approximately 14.6 per cent year-on-year growth, supported by higher revenue and improved gross profitability.
According to the company’s unaudited financial statements, revenue increased to Rs1.147 billion from Rs1.076 billion, while the cost of sales declined to Rs657.866 million from Rs736.731 million.
Consequently, gross profit rose substantially to Rs489.485 million, compared with Rs339.373 million a year earlier, representing an increase of approximately 44.2 per cent.
The company’s gross profit margin improved to approximately 42.7 per cent, compared with 31.5 per cent in the corresponding quarter last year.
The improvement indicates stronger gross profitability during the reporting period, with revenue growth accompanied by a reduction in the cost of sales.
Operating Profit Rises 30.4%
Otsuka Pakistan’s operating profit increased to Rs234.535 million during the quarter, compared with Rs179.864 million in the corresponding period last year.
This represents an increase of approximately 30.4 per cent.
However, the company also recorded higher operating expenditure.
Selling and distribution expenses increased to Rs179.104 million from Rs158.141 million, while administrative and general expenses rose to Rs53.890 million from Rs45.743 million.
Other income declined to Rs32.042 million from Rs64.034 million, while other expenses increased to Rs53.998 million from Rs19.658 million.
Finance costs also increased to Rs4.812 million, compared with Rs2.533 million in the corresponding quarter of 2025.
Despite these expenses, profit before taxation rose to Rs229.723 million from Rs177.212 million, an increase of approximately 29.6 per cent.
Taxation for the quarter amounted to Rs92.106 million, compared with Rs57.134 million last year.
Earnings Per Share Improve To Rs11.37
The company’s earnings per share increased to Rs11.37 for the quarter ended September 30, 2026, compared with Rs9.92 during the corresponding quarter last year.
The improvement reflects higher profitability attributable to shareholders.
Otsuka Pakistan’s Board of Directors did not recommend an interim cash dividend, bonus shares or rights issue alongside the quarterly financial results.
Otsuka Pakistan’s Quarterly Financial Performance
| Financial indicator | Jul–Sep 2026 | Jul–Sep 2025 |
| Revenue | Rs1,147.35m | Rs1,076.10m |
| Gross profit | Rs489.49m | Rs339.37m |
| Operating profit | Rs234.54m | Rs179.86m |
| Profit before tax | Rs229.72m | Rs177.21m |
| Net profit | Rs137.62m | Rs120.08m |
| Earnings per share | Rs11.37 | Rs9.92 |
| Gross profit margin | 42.7% | 31.5% |
Source: Otsuka Pakistan Limited’s unaudited financial statements for the quarter ended September 30, 2026. Figures rounded.
Production Line-II To Close As Rs81 Million Machinery Becomes Idle
Alongside the improved financial performance, Otsuka Pakistan has approved a significant operational restructuring at its manufacturing facility in Hub, Balochistan.
According to the company’s material information disclosure, the Board of Directors approved transferring the production of nine registered pharmaceutical solutions, each packaged in 1,000-millilitre containers, from Production Line-II to Production Line-I.
The transfer is scheduled to take effect on January 1, 2027.
Following the transfer, Production Line-II will be closed, leaving filling machinery with a carrying value of approximately Rs81 million idle.
The restructuring represents a consolidation of manufacturing activities at the company’s existing production facility.
Although the company has not quantified the expected financial impact of the restructuring, the decision indicates a reorganisation of manufacturing resources.
The disclosure does not specify whether the idle machinery will eventually be sold, relocated or repurposed.
Also Read: Indus Motor Profit Rises 10% To Rs7.4 Billion As Vehicle Sales Surge 34%
Nine Pharmaceutical Products Included In Restructuring
The manufacturing restructuring covers nine pharmaceutical solutions registered with the relevant regulatory authorities.
These include:
- Ringolact: Lactated Ringer’s Injection USP.
- Ringolact-D: 5% Dextrose and Lactated Ringer’s Injection USP.
- Plabolyte-M: 5% Dextrose and Electrolytes Injection.
- Plabolyte-40: 5% Dextrose and 0.3% Potassium Chloride.
- Pladex-5: 5% Dextrose.
- Pladexsal: Dextrose Saline.
- Plasaline: Normal Saline.
- Pladex-10: 10% Dextrose.
- Pladex-25: 25% Dextrose.
All nine formulations are registered in 1,000-millilitre pack sizes.
The products form part of Otsuka Pakistan’s pharmaceutical portfolio, including intravenous fluids and dextrose-based solutions used in healthcare settings.
Under the restructuring plan, manufacturing of these products will continue through Production Line-I from the beginning of 2027.
Company Plans Sale Of Pharmaceutical Product Rights
In another significant development, Otsuka Pakistan has announced its intention to transfer and sell selected pharmaceutical product authorisations, registrations and associated technical information.
The proposed transactions involve three ampoule products: Dextrose 25%, Potassium Chloride and Meylon.
According to the company’s regulatory disclosure, the proposed sale may also include associated inventory where applicable.
The company stated that it would undertake the necessary regulatory procedures and approvals before proceeding with the transactions.
It also plans to initiate a due diligence process involving potential purchasers.
The proposed transactions could result in the transfer of certain pharmaceutical product rights and related assets to prospective buyers.
However, the transactions remain subject to regulatory requirements and the completion of the necessary procedures.
Total Assets Reach Rs3.08 Billion
Otsuka Pakistan’s financial position also showed an increase in total assets during the first quarter of its financial year.
According to the company’s condensed interim statement of financial position, total assets stood at Rs3.082 billion as of September 30, 2026, compared with Rs3.022 billion at June 30, 2026.
Non-current assets increased to Rs712.898 million from Rs731.503 million at the end of June, reflecting a decline over the three-month period.
Property, plant and equipment stood at Rs668.503 million, compared with Rs661.792 million at June 30.
Current assets increased to Rs2.369 billion from Rs2.291 billion.
Stock-in-trade rose to Rs1.331 billion from Rs1.300 billion, reflecting an increase in inventory holdings.
Trade debts stood at Rs168.336 million, compared with Rs183.452 million at the end of the previous financial year.
The company’s reported bank balances amounted to Rs67.932 million, while short-term investments stood at Rs564.610 million.
Shareholders’ Equity Strengthens To Rs1.30 Billion
Otsuka Pakistan’s total shareholders’ equity increased to Rs1.299 billion as of September 30, 2026, compared with Rs1.161 billion at June 30, 2026.
The increase reflects the profit earned during the quarter.
Revenue reserves rose to Rs1.178 billion from Rs1.040 billion, while paid-up share capital remained unchanged at Rs121 million.
The company’s accumulated profits increased to Rs685.606 million, compared with Rs547.989 million at June 30, 2026.
The financial statements also showed a short-term loan from a related party amounting to Rs971.135 million, compared with Rs942.700 million at the end of June.
Trade and other payables stood at Rs799.483 million, compared with Rs990.958 million previously.
Total current liabilities declined to Rs1.777 billion from Rs1.861 billion.
The improvement in shareholders’ equity and reduction in current liabilities provide additional context to the company’s financial position as it prepares to reorganise its manufacturing operations.
Also Read: Sitara Chemical Shareholders Approve Sale Of 3,306 Kanal Land To Fund Expansion, Repay Loans
Operating Cash Flow Improves
The company’s cash flow statement showed net cash generated from operating activities of Rs146.931 million during the quarter, compared with Rs125.157 million in the corresponding period last year.
This represents an increase of approximately 17.4 per cent.
Cash generated from operations before finance costs, taxes and long-term loan movements stood at Rs165.851 million, compared with Rs163.022 million last year.
Otsuka Pakistan spent Rs41.346 million on additions to property, plant and equipment during the quarter, compared with Rs46.613 million in the corresponding period of 2025.
The company also reported Rs24.797 million in lease rental payments under financing activities.
Overall, net cash and cash equivalents increased by Rs80.788 million during the quarter.
Cash and cash equivalents at the end of the period stood at Rs632.542 million, compared with Rs457.361 million in the corresponding quarter of the previous year.
The cash flow figures indicate positive operating cash generation during the period, alongside continued investment in manufacturing assets.
Manufacturing Consolidation Comes Amid Improving Financial Performance
The simultaneous announcement of improved quarterly profitability and manufacturing restructuring represents an important development for Otsuka Pakistan.
The company has recorded higher revenue, stronger gross margins, increased operating profit and improved net earnings during the reporting period.
At the same time, the decision to consolidate manufacturing operations onto a single production line indicates a change in the organisation of its existing production infrastructure.
The planned closure of Production Line-II will leave machinery valued at approximately Rs81 million idle, while the proposed disposal of selected pharmaceutical product rights represents another component of the company’s operational reorganisation.
The restructuring could potentially affect the company’s future operating cost structure and asset utilisation, although the financial impact will depend on implementation and subsequent management decisions.
The company has not provided quantified forecasts of the savings or expenses associated with the restructuring.
Regulatory Compliance And Future Developments
Otsuka Pakistan submitted its material information disclosure to the Pakistan Stock Exchange in accordance with Sections 96 and 131 of the Securities Act, 2015, and Clause 5.6.1(a) of the PSX Rule Book.
The company stated that the disclosures were being made in the interest of transparency and compliance with applicable regulatory requirements.
It also confirmed that any subsequent material developments would be communicated to the PSX in accordance with relevant laws and regulations.
With production consolidation scheduled for January 2027 and the proposed sale of selected pharmaceutical rights awaiting further procedures, Otsuka Pakistan enters the next phase of its operations with improved quarterly profitability and a significant manufacturing reorganisation underway.